Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL9837052 | 0.98 | KDM4E (0.42) | KDM4EMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL7288734 | 0.86 | KMT2A (0.42) | MAPTMEN1KMT2APOLBEGLN1 | |
| SCHEMBL20674232 | 0.80 | BRD4 (0.45) | KDM4EMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL6050604 | 0.79 | BAZ2B (0.47) | KDM4EMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL9836198 | 0.74 | KDM4E (0.39) | KDM4EMAPTALDH1A1MAP2K2MAP2K1 | |
| SCHEMBL1497851 | 0.73 | CYP3A4 (0.37) | MEN1ALDH1A1KMT2AMAPK1POLB | |
| SCHEMBL1497856 | 0.73 | LMNA (0.36) | MAPTALDH1A1EGLN1 | |
| SCHEMBL9834409 | 0.73 | KDM4E (0.41) | KDM4EKMT2AMAPK1PKMMAP2K2 | |
| SCHEMBL21955856 | 0.71 | MEN1 (0.46) | MAPTMEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL7288748 | 0.71 | HTR3A (0.48) | MEN1ALDH1A1KMT2AMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0269295-B1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1991-06-26 | — | — | EP | claimed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | claimed |
| EP-0269295-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1988-06-01 | — | — | EP | claimed |
| US-6995173-B2 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1355647-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. Alamo Ventures I, LLC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC | 2003-07-10 | — | — | US | disclosed |
| US-6562838-B2 | Providing subject suffering from a symptoms of cardiovascular disease and a purified enantiomer preparation of flosequinan; administering preparation to subject under conditions such that symptom is reduced | R. T. ALAMO VENTURES I, L.L.C. | 2003-05-13 | — | — | US | disclosed |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-10 | — | — | US | disclosed |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C, | 2002-10-03 | — | — | US | disclosed |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6458804-B1 | UTILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING QUINOLINONES (AND DERIVATIVES THEREOF) IN PATIENTS WITH SYMPTOMS OF A CENTRAL NERVOUS SYSTEM DISORDER WHO ARE OTHERWISE FREE OF CARDIAC DISEASE AND/OR WHO HAVE NOT BEEN | R.T. ALAMO VENTURESI, LLC | 2002-10-01 | — | — | US | disclosed |
| US-6451813-B1 | Treatment of gastroparesis in certain patient groups | R. T. ALAMO VENTURES I, LLC | 2002-09-17 | — | — | US | disclosed |
| WO-2002058703-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. ALAMO VENTURES I, LLC (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0269295-B1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
| EP-0269295-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | KDM4E 871/4885MAPT 4208/4885MEN1 3691/4885 |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | PMP22, NLN, SLC6A2 | KDM4E 4359/4885MAPT 617/4885MEN1 2410/4885 |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | KDM4E 871/4885MAPT 4208/4885MEN1 3691/4885 |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | PMP22, NLN, SLC6A2 | KDM4E 4359/4885MAPT 617/4885MEN1 2410/4885 |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | FABP6, SLC10A2, FABP2 | KDM4E 4676/4885MAPT 4569/4885MEN1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.